Work

P2.10A.05 Ipat-Lung: A Multi-Center Phase 2 Study of Ipatasertib Plus Docetaxel in NSCLC Patients who Have Failed or Are Intolerant to 1st Line Immunotherapy

Year: 2024

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2024.09.440

Authors: J. Zhang, C.H. Huang, P.C. Neupane, R. Chuda, R.J. McKittrick, M.R. Allen, Q. Dai, Z. Collins, R. Madan, M.A. Phadnis, C. Zhong, M. Furqan, Z. Hao

Institutions: University of Kansas Medical Center, University of Kansas, University of Iowa, University of Kentucky, Markey Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403419795

FWCI: 0.581

Cites:

Cited by: 2

Related to: 10